Compare Stocks: PLX, VSTM, GERN, and ANNX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$3.75 -1.6%	$4.33	$2.54 ▼ $7.18	$722.30M	1.32	3.87 million shs	2.58 million shs
GERN Geron	$1.12 -0.9%	$1.34	$1.04 ▼ $2.01	$725.99M	0.61	7.72 million shs	11.23 million shs
PLX Protalix BioTherapeutics	$2.55 -0.8%	$2.63	$1.65 ▼ $3.19	$205.46M	-0.09	910,418 shs	383,907 shs
VSTM Verastem	$10.04 -0.2%	$7.91	$3.43 ▼ $10.82	$911.07M	0.39	5.36 million shs	3.76 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	-1.57%	+9.97%	-3.10%	-28.16%	+25.00%
GERN Geron	-0.88%	-4.27%	-9.68%	-21.13%	-9.68%
PLX Protalix BioTherapeutics	-0.78%	-2.67%	-8.93%	+7.59%	+12.33%
VSTM Verastem	-0.20%	+16.07%	+22.74%	+65.95%	+27.74%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$3.75 -1.6%	$4.33	$2.54 ▼ $7.18	$722.30M	1.32	3.87 million shs	2.58 million shs
GERN Geron	$1.12 -0.9%	$1.34	$1.04 ▼ $2.01	$725.99M	0.61	7.72 million shs	11.23 million shs
PLX Protalix BioTherapeutics	$2.55 -0.8%	$2.63	$1.65 ▼ $3.19	$205.46M	-0.09	910,418 shs	383,907 shs
VSTM Verastem	$10.04 -0.2%	$7.91	$3.43 ▼ $10.82	$911.07M	0.39	5.36 million shs	3.76 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	-1.57%	+9.97%	-3.10%	-28.16%	+25.00%
GERN Geron	-0.88%	-4.27%	-9.68%	-21.13%	-9.68%
PLX Protalix BioTherapeutics	-0.78%	-2.67%	-8.93%	+7.59%	+12.33%
VSTM Verastem	-0.20%	+16.07%	+22.74%	+65.95%	+27.74%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANNX Annexon	2.40	Hold	$15.29	307.62% Upside
GERN Geron	2.20	Hold	$4.00	257.14% Upside
PLX Protalix BioTherapeutics	3.00	Buy	$12.00	370.59% Upside
VSTM Verastem	2.77	Moderate Buy	$16.67	66.00% Upside

Current Analyst Ratings Breakdown

Latest PLX, VSTM, GERN, and ANNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/21/2026	GERN Geron	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/16/2026	VSTM Verastem	Benchmark Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/16/2026	VSTM Verastem	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$13.00 ➝ $14.00
10/15/2026	ANNX Annexon	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	VSTM Verastem	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/15/2026	VSTM Verastem	Alliance Global Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/15/2026	VSTM Verastem	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$14.00 ➝ $19.00
10/15/2026	VSTM Verastem	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$18.00 ➝ $24.00
10/14/2026	VSTM Verastem	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$11.00 ➝ $13.00
10/8/2026	VSTM Verastem	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/5/2026	VSTM Verastem	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$18.00

(Data available from 10/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANNX Annexon	N/A	N/A	N/A	N/A	$1.42 per share	N/A
GERN Geron	$183.88M	3.91	N/A	N/A	$0.35 per share	3.20
PLX Protalix BioTherapeutics	$80.62M	2.55	$0.14 per share	17.80	$0.47 per share	5.43
VSTM Verastem	$30.91M	29.42	N/A	N/A	$0.74 per share	13.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANNX Annexon	-$206.69M	-$1.16	N/A	N/A	N/A	N/A	-106.15%	-79.82%	11/9/2026 (Estimated)
GERN Geron	-$83.50M	-$0.11	N/A	18.67	N/A	-34.17%	-24.48%	-10.30%	11/4/2026 (Estimated)
PLX Protalix BioTherapeutics	$8.31M	$0.23	N/A	8.23	N/A	-21.03%	-30.89%	-11.74%	N/A
VSTM Verastem	-$209.47M	-$2.66	N/A	N/A	N/A	-231.59%	-467.49%	-94.54%	11/5/2026 (Estimated)

Latest PLX, VSTM, GERN, and ANNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	ANNX Annexon	-$0.28	N/A	N/A	N/A	$3.50 million	N/A
11/5/2026	Q3 2026	VSTM Verastem	-$0.44	N/A	N/A	N/A	$26.58 million	N/A
11/4/2026	Q3 2026	GERN Geron	-$0.01	N/A	N/A	N/A	$60.36 million	N/A
8/12/2026	Q2 2026	ANNX Annexon	-$0.2388	-$0.28	-$0.0412	-$0.28	$6.50 million	N/A
8/6/2026	Q2 2026	VSTM Verastem	-$0.4305	-$0.35	+$0.0805	-$0.35	$22.88 million	$40.08 million
8/5/2026	Q2 2026	GERN Geron	-$0.0089	-$0.02	-$0.0111	-$0.02	$55.30 million	$57.48 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
GERN Geron	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANNX Annexon	N/A	5.53	5.53
GERN Geron	0.55	6.91	5.16
PLX Protalix BioTherapeutics	N/A	1.98	1.27
VSTM Verastem	1.48	2.25	2.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANNX Annexon	N/A
GERN Geron	73.71%
PLX Protalix BioTherapeutics	16.53%
VSTM Verastem	88.37%

Insider Ownership

Company	Insider Ownership
ANNX Annexon	10.31%
GERN Geron	1.71%
PLX Protalix BioTherapeutics	6.70%
VSTM Verastem	1.94%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANNX Annexon	92	189.58 million	170.03 million	Optionable
GERN Geron	258	642.47 million	631.49 million	Optionable
PLX Protalix BioTherapeutics	226	80.57 million	69.00 million	Optionable
VSTM Verastem	102	90.56 million	88.81 million	Optionable

PLX, VSTM, GERN, and ANNX Headlines

Recent News About These Companies

Verastem consensus price target increased by 17.42% to $17.57

October 23 at 12:05 AM | msn.com

What Verastem (VSTM)'s Trial Update Means For Shareholders

October 23 at 12:05 AM | finance.yahoo.com

Verastem Oncology prices USD 250 million offering for Verastem Oncology stock

October 22 at 7:33 PM | ad-hoc-news.deA

Verastem (NASDAQ:VSTM) Stock Price Up 8% - Time to Buy?

October 22 at 6:59 PM | marketbeat.com

Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026

October 22 at 7:30 AM | businesswire.com

Analysts Are Bullish on These Healthcare Stocks: Verastem (VSTM), BioNTech SE (BNTX)

October 21 at 7:16 AM | theglobeandmail.com

Verastem names CEO successor. Verastem Oncology stock has USD 780.7 million value

October 21 at 1:20 AM | ad-hoc-news.deA

Verastem (NASDAQ:VSTM) Stock Price Expected to Rise, Mizuho Analyst Says

October 18, 2026 | americanbankingnews.com

Verastem (NASDAQ:VSTM) Stock Price Expected to Rise, BTIG Research Analyst Says

October 17, 2026 | americanbankingnews.com

Verastem (NASDAQ:VSTM) Stock Price Up 8% on Analyst Upgrade

October 17, 2026 | americanbankingnews.com

Verastem Announces $234.7 Million Underwritten Offering Priced at $8.00 Per Share

October 16, 2026 | kalkinemedia.comK

Verastem (NASDAQ:VSTM) Stock Price Target Raised at Mizuho

October 16, 2026 | marketbeat.com

Verastem, Inc. (NASDAQ:VSTM) Stock Has Consensus Price Target of $16.50

October 16, 2026 | americanbankingnews.com

Verastem, Inc. (VSTM) - What Are Investment Firms Thinking About This Stock?

October 16, 2026 | marketbeat.com

VSTM Stock Clocks Best Day In 11 Months After Positive Cancer Drug Trial Update And Multiple Price-Target Hikes

October 15, 2026 | stocktwits.comS

Verastem (VSTM) Shares Jumped On Trial Data And Funding, Is The Stock Still Cheap?

October 15, 2026 | finance.yahoo.com

Verastem (NASDAQ:VSTM) Shares Up 8% on Analyst Upgrade

October 15, 2026 | marketbeat.com

Verastem (NASDAQ:VSTM) Stock Gets Price Target Increase from BTIG Research

October 15, 2026 | marketbeat.com

Verastem: A Real Pancreatic Cancer Drug, Arriving Second

October 15, 2026 | seekingalpha.com

Verastem prices $250m offering as KRAS drug heads to Phase III

October 15, 2026 | thepharmaletter.comT

Verastem Oncology's investigational drug delivers encouraging responses across multiple cancers

October 14, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PLX, VSTM, GERN, and ANNX Company Descriptions

Annexon NASDAQ:ANNX

$3.75 -0.06 (-1.57%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$3.96 +0.21 (+5.60%)

As of 10/23/2026 07:30 PM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Geron NASDAQ:GERN

$1.12 -0.01 (-0.88%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$1.11 -0.01 (-0.54%)

As of 10/23/2026 07:55 PM Eastern

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Protalix BioTherapeutics NYSE:PLX

$2.55 -0.02 (-0.78%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$2.54 0.00 (-0.20%)

As of 10/23/2026 07:30 PM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Verastem NASDAQ:VSTM

$10.04 -0.02 (-0.20%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$10.13 +0.09 (+0.93%)

As of 10/23/2026 07:55 PM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PLX, VSTM, GERN, and ANNX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PLX, VSTM, GERN, and ANNX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PLX, VSTM, GERN, and ANNX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PLX, VSTM, GERN, and ANNX Company Descriptions

Annexon NASDAQ:ANNX

Geron NASDAQ:GERN

Protalix BioTherapeutics NYSE:PLX

Verastem NASDAQ:VSTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PLX, VSTM, GERN, and ANNX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PLX, VSTM, GERN, and ANNX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PLX, VSTM, GERN, and ANNX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PLX, VSTM, GERN, and ANNX Company Descriptions

Annexon NASDAQ:ANNX

Geron NASDAQ:GERN

Protalix BioTherapeutics NYSE:PLX

Verastem NASDAQ:VSTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools